In vitro study on efficacy of SKF7®, a Malaysian medicinal plant product against SARS-CoV-2

2区 医学 Q1 Medicine BMC Complementary and Alternative Medicine Pub Date : 2024-09-11 DOI:10.1186/s12906-024-04628-6
Mohd Ridzuan Mohd Abd Razak, Nur Hana Md Jelas, Nor Azrina Norahmad, Norazlan Mohmad Misnan, Amirrudin Muhammad, Noorsofiana Padlan, Muhammad Nor Farhan Sa’at, Murizal Zainol, Ami Fazlin Syed Mohamed
{"title":"In vitro study on efficacy of SKF7®, a Malaysian medicinal plant product against SARS-CoV-2","authors":"Mohd Ridzuan Mohd Abd Razak, Nur Hana Md Jelas, Nor Azrina Norahmad, Norazlan Mohmad Misnan, Amirrudin Muhammad, Noorsofiana Padlan, Muhammad Nor Farhan Sa’at, Murizal Zainol, Ami Fazlin Syed Mohamed","doi":"10.1186/s12906-024-04628-6","DOIUrl":null,"url":null,"abstract":"In early 2020, COVID-19 pandemic has mobilized researchers in finding new remedies including repurposing of medicinal plant products focusing on direct-acting antiviral and host-directed therapies. In this study, we performed an in vitro investigation on the standardized Marantodes pumilum extract (SKF7®) focusing on anti-SARS-CoV-2 and anti-inflammatory activities. Anti-SARS-CoV-2 potential of the SKF7® was evaluated in SARS-CoV-2-infected Vero E6 cells and SARS-CoV-2-infected A549 cells by cytopathic effect-based assay and RT-qPCR, respectively. Target based assays were performed on the SKF7® against the S1-ACE2 interaction and 3CL protease activities. Anti-inflammatory activity of the SKF7® was evaluated by nitric oxide inhibitory and TLR2/TLR4 receptor blocker assays. The SKF7® inhibited wild-type Wuhan (EC50 of 21.99 µg/mL) and omicron (EC50 of 16.29 µg/mL) SARS-CoV-2 infections in Vero-E6 cells. The SKF7® also inhibited the wild-type SARS-CoV-2 infection in A549 cells (EC50 value of 6.31 µg/mL). The SKF7® prominently inhibited 3CL protease activity. The SKF7® inhibited the LPS induced-TLR4 response with the EC50 of 16.19 µg/mL. In conclusion, our in vitro study highlighted anti-SARS-CoV-2 and anti-inflammatory potentials of the SKF7®. Future pre-clinical in vivo studies focusing on antiviral and immunomodulatory potentials of the SKF7® in affecting the COVID-19 pathogenesis are warranted.","PeriodicalId":9132,"journal":{"name":"BMC Complementary and Alternative Medicine","volume":"17 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Complementary and Alternative Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12906-024-04628-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

In early 2020, COVID-19 pandemic has mobilized researchers in finding new remedies including repurposing of medicinal plant products focusing on direct-acting antiviral and host-directed therapies. In this study, we performed an in vitro investigation on the standardized Marantodes pumilum extract (SKF7®) focusing on anti-SARS-CoV-2 and anti-inflammatory activities. Anti-SARS-CoV-2 potential of the SKF7® was evaluated in SARS-CoV-2-infected Vero E6 cells and SARS-CoV-2-infected A549 cells by cytopathic effect-based assay and RT-qPCR, respectively. Target based assays were performed on the SKF7® against the S1-ACE2 interaction and 3CL protease activities. Anti-inflammatory activity of the SKF7® was evaluated by nitric oxide inhibitory and TLR2/TLR4 receptor blocker assays. The SKF7® inhibited wild-type Wuhan (EC50 of 21.99 µg/mL) and omicron (EC50 of 16.29 µg/mL) SARS-CoV-2 infections in Vero-E6 cells. The SKF7® also inhibited the wild-type SARS-CoV-2 infection in A549 cells (EC50 value of 6.31 µg/mL). The SKF7® prominently inhibited 3CL protease activity. The SKF7® inhibited the LPS induced-TLR4 response with the EC50 of 16.19 µg/mL. In conclusion, our in vitro study highlighted anti-SARS-CoV-2 and anti-inflammatory potentials of the SKF7®. Future pre-clinical in vivo studies focusing on antiviral and immunomodulatory potentials of the SKF7® in affecting the COVID-19 pathogenesis are warranted.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
马来西亚药用植物产品 SKF7® 对 SARS-CoV-2 的体外药效研究
2020 年初,COVID-19 大流行促使研究人员寻找新的疗法,包括重新利用药用植物产品,重点是直接作用抗病毒和宿主导向疗法。在本研究中,我们对标准化的马兰头提取物(SKF7®)进行了体外研究,重点研究其抗SARS-CoV-2和抗炎活性。在SARS-CoV-2感染的Vero E6细胞和SARS-CoV-2感染的A549细胞中,分别通过基于细胞病理效应的检测和RT-qPCR对SKF7®的抗SARS-CoV-2潜力进行了评估。对 SKF7® 的 S1-ACE2 相互作用和 3CL 蛋白酶活性进行了靶标检测。一氧化氮抑制和 TLR2/TLR4 受体阻断试验评估了 SKF7® 的抗炎活性。SKF7® 可抑制 Vero-E6 细胞中野生型武汉病毒(EC50 为 21.99 µg/mL)和欧米茄病毒(EC50 为 16.29 µg/mL)的 SARS-CoV-2 感染。SKF7® 还能抑制野生型 SARS-CoV-2 在 A549 细胞中的感染(EC50 值为 6.31 µg/mL)。SKF7® 能显著抑制 3CL 蛋白酶的活性。SKF7® 可抑制 LPS 诱导的 TLR4 反应,其 EC50 值为 16.19 µg/mL。总之,我们的体外研究强调了 SKF7® 的抗 SARS-CoV-2 和抗炎潜力。未来的临床前体内研究应侧重于 SKF7® 在影响 COVID-19 发病机制方面的抗病毒和免疫调节潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
BMC Complementary and Alternative Medicine
BMC Complementary and Alternative Medicine INTEGRATIVE & COMPLEMENTARY MEDICINE-
CiteScore
7.00
自引率
0.00%
发文量
0
审稿时长
3 months
期刊介绍: BMC Complementary Medicine and Therapies is an open access journal publishing original peer-reviewed research articles on interventions and resources that complement or replace conventional therapies, with a specific emphasis on research that explores the biological mechanisms of action, as well as their efficacy, safety, costs, patterns of use and/or implementation.
期刊最新文献
Varieties of silence – a mixed-methods study exploring reasons and justifications for nondisclosure of the use of complementary therapies to physicians in Finland In vitro study on efficacy of SKF7®, a Malaysian medicinal plant product against SARS-CoV-2 Insights into free radicals scavenging, α-Amylase inhibition, cytotoxic and antifibrotic activities unveiled by Peganum harmala extracts Correction: Antimalarial efficacy test of the aqueous crude leaf extract of Coriandrum sativum Linn.: an in vivo multiple model experimental study in mice infected with Plasmodium berghei Medicinal plants used in multiple sclerosis patients, prevalence and associated factors: a descriptive cross-sectional study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1